Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Codexis, Inc.NASDAQ: CDXS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $10.31M fell 20.3% year over year, behind the -0.5% change in trailing-twelve-month research & development. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at -13.2% a year.
Context
- Research & development amounted to 74.3% of revenue in FY2025, down 3.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -20.3% toward the trailing-twelve-month pace of -0.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 52.31M USD
- Year-over-year change
- +13.1%
- 4-year CAGR
- -1.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.31M | +13.1% |
| FY2024 | 2024-12-31 | 46.26M | -21.4% |
| FY2023 | 2023-12-31 | 58.89M | -26.5% |
| FY2022 | 2022-12-31 | 80.1M | +43.2% |
| FY2021 | 2021-12-31 | 55.92M | — |
Research & Development vs competitors
How CDXS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.5% is the 4th highest of 10, against a peer median of -15.8%.
- Research & development amounts to 61.1% of revenue for CDXS, versus a peer median of 460.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.23M USD | +11.4% | -23.3% | 327.7% | |
| LTM Mar 2026 | $101.77M USD | -11.6% | -4.0% | 291.9% | |
| LTM Mar 2026 | $58.4M USD | -50.0% | -40.2% | 104.5% | |
| LTM Mar 2026 | $47.7M USD | -0.5% | -13.2% | 61.1% | |
| LTM Mar 2026 | $46.96M USD | +41.8% | +36.4% | — | |
| LTM Mar 2026 | $44.75M USD | -15.8% | -0.4% | 154.8% | |
| FY2025 | €43.62M EUR | -16.1% | -5.5% | 1565.1% | |
| LTM Mar 2026 | $24.4M USD | -23.4% | -12.2% | 824.8% | |
| LTM Mar 2026 | $18.8M USD | -26.8% | -18.0% | 593.1% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $17.59M USD | +68.3% | +29.6% | 902.4% |
| Peer median (excluding CDXS) | — | -15.8% | -5.5% | 460.4% | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 104.75M | 138.59M | 70.14M | 59.35M | 70.39M |
| Cost of Revenue | 22.21M | 38.03M | 12.81M | 16.29M | 9.34M |
| Gross Profit | 82.55M | 100.56M | 57.33M | 43.06M | 61.05M |
| Gross Margin | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% |
| Research & Development | 55.92M | 80.1M | 58.89M | 46.26M | 52.31M |
| Selling, General & Admin | 49.32M | 52.17M | 53.25M | 55.15M | 47.07M |
| Operating Expenses | 105.24M | 135.44M | 125.4M | 101.58M | 99.38M |
| Depreciation & Amortization | 5.95M | 5.4M | 5.52M | 4.95M | 5.25M |
| EBITDA | (15.14M) | (26.31M) | (49.28M) | (53.41M) | (33.87M) |
| EBITDA Margin | -14.5% | -19.0% | -70.3% | -90.0% | -48.1% |
| Operating Income | (22.7M) | (34.88M) | (68.07M) | (58.52M) | (38.33M) |
| Operating Margin | -21.7% | -25.2% | -97.0% | -98.6% | -54.5% |
| Interest Income | 459K | 1.44M | 4.17M | 3.67M | 2.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 4.81M |
| Other Income / Expenses | 1.61M | 1.57M | (8.1M) | (6.72M) | (5.6M) |
| Income Before Tax | (21.09M) | (33.32M) | (76.17M) | (65.24M) | (43.93M) |
| Pre-Tax Margin | -20.1% | -24.0% | -108.6% | -109.9% | -62.4% |
| Income Tax Expense | 189K | 276K | 69K | 34K | 47K |
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Net Margin | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| EPS (Basic) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| EPS (Diluted) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| Weighted Avg Shares | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
| Weighted Avg Shares (Diluted) | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.